Still ‘Work To Be Done’ After Ranibizumab Approval, Says Samsung Bioepis
Executive Kyung-Ah Kim Sees Opportunity To Lead On Ophthalmic Biosimilars
• By David Wallace
Samsung Bioepis recently gained the first US ophthalmic biosimilar approval • Source: Alamy 
